1538 related articles for article (PubMed ID: 15829326)
1. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
Unsal M; Erturk D
Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
5. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
Kim YH; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Cancer; 2008 Nov; 113(9):2518-23. PubMed ID: 18780323
[TBL] [Abstract][Full Text] [Related]
6. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
Shepherd FA; Evans WK; MacCormick R; Feld R; Yau JC
Cancer Treat Rep; 1987 Oct; 71(10):941-4. PubMed ID: 2820571
[TBL] [Abstract][Full Text] [Related]
8. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
[TBL] [Abstract][Full Text] [Related]
10. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
[TBL] [Abstract][Full Text] [Related]
11. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK;
J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
[TBL] [Abstract][Full Text] [Related]
13. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial.
Gatzemeier U; Pawel JV; Laumen R; Hossfeld DK; Neuhauss R
Semin Oncol; 1994 Jun; 21(3 Suppl 6):31-5. PubMed ID: 8052871
[TBL] [Abstract][Full Text] [Related]
14. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
[TBL] [Abstract][Full Text] [Related]
16. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group.
Urban T; Chastang C; Lebas FX; Duhamel JP; Adam G; Darse J; Bréchot JM; Lebeau B
Cancer; 1999 Dec; 86(11):2238-45. PubMed ID: 10590363
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
Tsuchiya R; Suzuki K; Ichinose Y; Watanabe Y; Yasumitsu T; Ishizuka N; Kato H
J Thorac Cardiovasc Surg; 2005 May; 129(5):977-83. PubMed ID: 15867769
[TBL] [Abstract][Full Text] [Related]
18. [Dose-response effect of drugs in the chemotherapy of small-cell bronchial carcinoma].
Kostić D; Jelić S; Radulović S
Srp Arh Celok Lek; 2000; 128(3-4):75-9. PubMed ID: 10932613
[TBL] [Abstract][Full Text] [Related]
19. [Teniposide and cisplatin compared with etoposide and cisplatin for treatment of small cell lung cancer].
Fan Y; Huang ZY; Zhang YP; Sun L
Ai Zheng; 2002 Dec; 21(12):1368-71. PubMed ID: 12520751
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.
Jacot W; Pujol JL; Chakra M; Molinier O; Bozonnat MC; Gervais R; Quantin X
Lung Cancer; 2012 Feb; 75(2):213-6. PubMed ID: 21831476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
